137 related articles for article (PubMed ID: 35768393)
61. GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies.
Hosoi Y; Suzuki-Sakao M; Terada T; Konishi T; Ouchi Y; Miyajima H; Kono S
J Neurol; 2013 Dec; 260(12):3086-92. PubMed ID: 24091766
[TBL] [Abstract][Full Text] [Related]
62. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association?
Lacruz Ballester L; Fernandez-Fournier M; Puertas Muñoz I; Rodriguez Fraga O; Lastras Fernandez-Escandon C; Rodriguez de Rivera Garrido FJ; Alba Suarez EM; Tallon Barranco A
Neurol Sci; 2022 Jan; 43(1):633-641. PubMed ID: 33914193
[TBL] [Abstract][Full Text] [Related]
63. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
64. Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: a case series.
Incecik F; Herguner OM; Besen S; Yılmaz M
Acta Neurol Belg; 2018 Sep; 118(3):411-414. PubMed ID: 29349679
[TBL] [Abstract][Full Text] [Related]
65. Square-Wave Ocular Oscillation and Ataxia in an Anti-GAD-Positive Individual With Hypothyroidism.
Brokalaki C; Kararizou E; Dimitrakopoulos A; Evdokimidis I; Anagnostou E
J Neuroophthalmol; 2015 Dec; 35(4):390-5. PubMed ID: 26035807
[TBL] [Abstract][Full Text] [Related]
66. Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus.
Folli F; Daniele G; Werner S; Kamath S; Munera JV; Abboud H; Fanti P
Acta Diabetol; 2015 Oct; 52(5):897-903. PubMed ID: 25753172
[TBL] [Abstract][Full Text] [Related]
67. Nonparaneoplastic autoimmune cerebellar ataxias.
Joubert B; Honnorat J
Curr Opin Neurol; 2019 Jun; 32(3):484-492. PubMed ID: 30694927
[TBL] [Abstract][Full Text] [Related]
68. Autoimmune Polyglandular Syndrome with Refractory Gait Disturbance.
Takeuchi Y; Nomura T; Nakahara K; Ueda M
Intern Med; 2023 Jul; 62(14):2133-2137. PubMed ID: 36450465
[TBL] [Abstract][Full Text] [Related]
69. Vertical nystagmus associated with glutamic acid decarboxylase antibodies responding to cyclophosphamide.
Baizabal-Carvallo JF; Alonso-Juarez M
J Neuroimmunol; 2018 Apr; 317():5-7. PubMed ID: 29501085
[TBL] [Abstract][Full Text] [Related]
70. Anti-glutamic acid decarboxylase antibody positive neurological syndromes.
Tohid H
Neurosciences (Riyadh); 2016 Jul; 21(3):215-22. PubMed ID: 27356651
[TBL] [Abstract][Full Text] [Related]
71. Neurologic disorders associated with anti-glutamic acid decarboxylase antibodies: A comparison of anti-GAD antibody titers and time-dependent changes between neurologic disease and type I diabetes mellitus.
Nakajima H; Nakamura Y; Inaba Y; Tsutsumi C; Unoda K; Hosokawa T; Kimura F; Hanafusa T; Date M; Kitaoka H
J Neuroimmunol; 2018 Apr; 317():84-89. PubMed ID: 29338930
[TBL] [Abstract][Full Text] [Related]
72. Autoantibodies against eukaryotic translation elongation factor 1 delta in two patients with autoimmune cerebellar ataxia.
Guo L; Ren H; Fan S; Chao X; Liu M; Guan H; Wang J
Front Immunol; 2023; 14():1289175. PubMed ID: 38332912
[TBL] [Abstract][Full Text] [Related]
73. Response to steroid treatment in anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia, stiff person syndrome and polyendocrinopathy.
Kim JY; Chung EJ; Kim JH; Jung KY; Lee WY
Mov Disord; 2006 Dec; 21(12):2263-4. PubMed ID: 17013903
[No Abstract] [Full Text] [Related]
74. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase.
Ishida K; Mitoma H; Song SY; Uchihara T; Inaba A; Eguchi S; Kobayashi T; Mizusawa H
Ann Neurol; 1999 Aug; 46(2):263-7. PubMed ID: 10443895
[TBL] [Abstract][Full Text] [Related]
75. Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.
Kandasamy N; Lennox G; Annamalai AK; Maguire G; Adler AI
Endocr Pract; 2012; 18(4):e65-8. PubMed ID: 22297059
[TBL] [Abstract][Full Text] [Related]
76. [Autoantibody to glutamate decarboxylase in a patient with spinocerebellar degeneration and Sjögren syndrome].
Ikeda J; Harada T; Kamei H; Nakamura S
No To Shinkei; 1998 Feb; 50(2):177-80. PubMed ID: 9513208
[TBL] [Abstract][Full Text] [Related]
77. Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) Presenting with Pure Cerebellar Ataxia.
Termsarasab P; Pitakpatapee Y; Frucht SJ; Srivanitchapoom P
Tremor Other Hyperkinet Mov (N Y); 2018; 8():585. PubMed ID: 30191089
[TBL] [Abstract][Full Text] [Related]
78. Anti-Tr/DNER antibody-associated cerebellar ataxia: three rare cases report and literature review.
Cai Y; Liu J; Ren H; Shi F; Che J; Geng Q; Tan Y; Guan H; Di W
Neurol Sci; 2023 Jan; 44(1):397-403. PubMed ID: 36094774
[TBL] [Abstract][Full Text] [Related]
79. Rapidly progressing cerebellar ataxia associated with anti-GAD antibodies.
Quintas S; Ruiz RL; Zapata-Wainberg G; Vivancos J
Neurologia (Engl Ed); 2018 May; 33(4):273-275. PubMed ID: 27091680
[No Abstract] [Full Text] [Related]
80. [A case of persistent cerebellar ataxia complicated by conversion disorder--confirmed by positive cerebrospinal fluid glutamate receptor delta2 and epsilon2 antibodies].
Usui D; Mitsuda N; Hosokawa T; Fujieda M; Takahashi Y; Wakiguchi H
No To Hattatsu; 2011 Jan; 43(1):41-5. PubMed ID: 21400931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
